TAIPEI, Taiwan – For Western biopharmaceutical executives seeking an entry point into Asia, Taiwan may be a good gateway. And for Taiwanese innovators in need of outside partners to back still under-the-radar drug candidates: be more aggressive. Those were a few of the messages heard at the second annual Biologics World Taiwan conference here.